Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408663 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of EXT608 in Healthy Adults
A Phase 1 study of Safety Issues, sponsored by Extend Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05408663: Completed Phase 1 study of Safety Issues, sponsored by Extend Biosciences.
NCT05408663 is a Phase 1 study of Safety Issues that has completed, run by Extend Biosciences. The registered enrollment target is 24 participants, below the 118-participant average among 13 other Safety Issues trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05408663, a Phase 1 study of Safety Issues, has completed, sponsored by Extend Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.
Primary Outcome
Incidence, nature and severity of adverse events (AEs) and withdrawals due to Treatment-Emergent Adverse Events (TEAEs)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG EXT608
Study Locations (1)
Kansas
- PRA - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 1 |
What the finished NCT05408663 record still lists
NCT05408663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 118-participant average among 13 other Safety Issues trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Safety Issues appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05408663 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05408663 about?
NCT05408663 is a clinical study titled "A Phase 1 Study of EXT608 in Healthy Adults". This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will rec...
What is the current status of trial NCT05408663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-07-21. Estimated completion is 2023-06-13.
What conditions does trial NCT05408663 study?
This clinical trial studies the following conditions: Safety Issues.
What interventions are being tested in trial NCT05408663?
The interventions under investigation include: Placebo (OTHER), EXT608 (DRUG).
Who is sponsoring clinical trial NCT05408663?
This trial is sponsored by Extend Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05408663 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety Issues
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05408663's enrollment target sits among peer trials
24 9th of 13 higher than 5 of 13 other Safety Issues trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Safety Issues trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults
ACTIVE NOT RECRUITING · Phase 1
-
Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study
COMPLETED · Phase 1
-
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
COMPLETED · Phase 1
-
Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI